指南与共识腹部泌尿生殖CTMRPET

法国国家ENDOCAN-COMETE网络肾上腺皮质癌管理指南

[Guidelines of the French National ENDOCAN-COMETE, Association of Endocrine Surgery, Society of Urology for the management of adrenocortical carcinoma].
指南 / 共识 · Bull Cancer · 2023-04-13

该指南由法国国家ENDOCAN-COMETE网络等多学科专家制定,更新了成人肾上腺皮质癌的管理建议。肾上腺皮质癌是起源于肾上腺皮质的恶性肿瘤,以Weiss评分≥3定义,预后差且主要取决于诊断时的分期。指南涵盖从发现、诊断、治疗到随访的11个章节,强调所有局限性肿瘤的R0切除应在专家中心进行。

要点

  • 肾上腺皮质癌以Weiss评分≥3定义,预后主要取决于诊断时分期。
  • 所有局限性肾上腺皮质癌的R0切除仍是未满足的需求,须在专家中心完成。
  • 指南提供局限性、复发或晚期肾上腺皮质癌的治疗流程图。

核心结论

  • 肾上腺皮质癌是起源于肾上腺皮质的原发性恶性肿瘤,以Weiss评分≥3定义,预后差且主要取决于诊断时的分期。
  • 所有局限性肾上腺皮质癌的R0切除仍是未满足的需求,必须在专家中心进行。
  • 指南提供了局限性、复发或晚期肾上腺皮质癌的治疗流程图。

研究设计与样本

  • 该指南由法国国家ENDOCAN-COMETE网络专家撰写,并经法国内分泌学、肿瘤内科、内分泌外科、泌尿外科、病理学、遗传学、核医学、放射学、介入放射学等所有相关学会验证。
  • 指南基于文献中最稳健的数据更新,分为11个章节:发现情况、治疗前评估、诊断、肿瘤遗传学、预后分类、激素分泌过多治疗、局限性疾病治疗、复发治疗、晚期疾病治疗、随访、妊娠期特殊病例。

诊断标准与关键数值

  • 肾上腺皮质癌定义为Weiss评分≥3。

临床应用与阅片要点

  • 所有局限性肾上腺皮质癌的R0切除应在专家中心进行。
  • 治疗管理应参照指南提供的局限性、复发或晚期肾上腺皮质癌流程图。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

The adrenocortical carcinoma (ACC) is a primary malignant tumor developed from the adrenal cortex, defined by a Weiss score≥3. Its prognosis is poor and depends mainly on the stage of the disease at diagnosis. Care is organized in France by the multidisciplinary expert centers of the national ENDOCAN-COMETE "Adrenal Cancers" network, certified by the National Cancer Institute. This document updates the guidelines for the management of ACC in adults based on the most robust data in the literature. It's divided into 11 chapters: (1) circumstances of discovery; (2) pre-therapeutic assessment; (3) diagnosis of ACC; (4) oncogenetics; (5) prognostic classifications; (6) treatment of hormonal hypersecretion; (7) treatment of localized forms; (8) treatment of relapses; (9) treatment of advanced forms; (10) follow-up; (11) the particular case of ACC and pregnancy. R0 resection of all localized ACC remains an unmet need and it must be performed in expert centers. Flow-charts for the therapeutic management of localized ACC, relapse or advanced ACC are provided. It was written by the experts from the national ENDOCAN-COMETE network and validated by all French Societies involved in the management of these patients (endocrinology, medical oncology, endocrine surgery, urology, pathology, genetics, nuclear medicine, radiology, interventional radiology).

来源:Bull Cancer,查看原文。版权归原作者所有。

引用

  1. Libé, Haissaguerre, Renaudin, et al. [Guidelines of the French National ENDOCAN-COMETE, Association of Endocrine Surgery, Society of Urology for the management of adrenocortical carcinoma]. Bull Cancer. 2023. PMID: 37061367. doi:10.1016/j.bulcan.2023.03.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。